Department of Urology, Mayo Clinic, Rochester, MN.
Mayo Medical School, Mayo Clinic, Rochester, MN.
Urology. 2022 Mar;161:118-124. doi: 10.1016/j.urology.2021.11.035. Epub 2021 Dec 27.
To evaluate surgical outcomes stratified by posterior urethral obstruction (PUO) etiology in men undergoing definitive robotic posterior urethral reconstruction.
A retrospective, single surgeon, review of men undergoing robotic posterior urethral reconstruction between 2018 and 2020 was performed. Differences in complications, reconstructive success (no further intervention), and urinary continence by PUO etiology were assessed.
Robotic posterior urethral reconstruction was performed in 21 men. PUO etiology included benign prostatic hypertrophy treatment in 5 (24%), prostatectomy in 10 (48%), radiation in 5 (24%), and trauma in 1 (5%). Median number of prior endoscopic treatments was 3 (benign prostatic hypertrophy), 3 (prostatectomy), and 2 (radiation) with an average time between obstruction and reconstruction of 9, 12, and 15 months (P = .52). Median length of stay after reconstruction was 2, 1, and 2 days (P = .45). Thirty-day complications occurred in 0%, 20%, 40% (P = .19). Post-reconstruction re-intervention was necessary in 0%, 10%, 80% (P = .004). Ultimately, anatomic success was achieved in 100%, 90%, 80% (P = .63), with functional success rates of 100%, 100%, 60% (P = .035). Median postoperative pad/day usage was 0,0, 10.5 (P <.001), and ultimately 0%, 30%, 80% (P = .013) underwent artificial urinary sphincter placement.
Endoscopic treatment of posterior urethral obstruction (PUO) secondary to benign and malignant prostate conditions is associated with a high incidence of treatment failure. Robotic posterior urethral reconstruction is a safe and effective surgical solution for men with PUO in the absence of pelvic radiation. Men with pelvic radiation appear to be at increased risk of complications, PUO recurrence, and clinically significant stress urinary incontinence.
评估男性接受机器人后尿道重建术时,根据后尿道梗阻(PUO)病因分层的手术结果。
回顾性分析了 2018 年至 2020 年间接受机器人后尿道重建术的单外科医生病例。评估了不同病因引起的并发症、重建成功率(无需进一步干预)和尿控情况。
21 名男性接受了机器人后尿道重建术。PUO 病因包括良性前列腺增生治疗 5 例(24%)、前列腺切除术 10 例(48%)、放疗 5 例(24%)和创伤 1 例(5%)。良性前列腺增生治疗组、前列腺切除术组和放疗组的内镜治疗中位数分别为 3 次、3 次和 2 次,梗阻与重建之间的平均时间分别为 9、12 和 15 个月(P=0.52)。重建后平均住院时间分别为 2、1 和 2 天(P=0.45)。30 天并发症发生率分别为 0%、20%和 40%(P=0.19)。重建后需要再次干预的分别为 0%、10%和 80%(P=0.004)。最终,解剖学成功率分别为 100%、90%和 80%(P=0.63),功能成功率分别为 100%、100%和 60%(P=0.035)。术后平均尿垫/天使用量分别为 0、0、10.5(P<0.001),最终分别为 0%、30%和 80%(P=0.013)接受了人工尿道括约肌植入。
良性和恶性前列腺疾病继发的后尿道梗阻(PUO)的内镜治疗,其治疗失败率较高。机器人后尿道重建术是无骨盆放疗的男性 PUO 的安全有效手术解决方案。接受骨盆放疗的男性并发症、PUO 复发和有临床意义的压力性尿失禁风险增加。